---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-032182"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:47:06.642326+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance

## Summary
- GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
- FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.
- Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).
- New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).
- Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase.

## SEC filing metadata
- accession: 0001628280-24-032182
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/0001628280-24-032182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/abt-20240718.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-032182
- JSON: https://secwatch.observer/filing/0001628280-24-032182.json
- Plain text: https://secwatch.observer/filing/0001628280-24-032182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.